IL1A and Parkinson disease: Thus, it is plausible that the higher sIL-1R2 plasma levels in our PD patients compared to the healthy controls might reflect PD associated inflammation and the presence of a similar compensatory mechanism aimed to counterbalance the IL-1 pro-inflammatory effects in the disease (Mantovani et al., 2019).